April 8 (Reuters) - Recce Pharmaceuticals Ltd RCE.AX :
* FORMALISED PHASE I CLINICAL TRIAL AGREEMENT TO CONDUCT FIRST-IN-HUMAN STUDY OF COMPOUND RECCE 327 IN 40 HEALTHY SUBJECTS
* FIRST PATIENTS IN THIS STUDY ARE EXPECTED TO BE DOSED IN SECOND HALF OF 2020
* PHASE I TRIAL AGREEMENT WITH LEADING CLINICAL RESEARCH ORGANIZATION PAREXEL